Skip to main content
Springer Nature Link
Log in

Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck

  • Original
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Objective

The identification of a reliable circulating tumor marker in squamous cell carcinoma of the head and neck (SCCHN) could assist in diagnosis and monitoring response to therapy.

Aim

The aim of this study was to investigate the effectiveness of the serum tumor markers CYFRA 21-1, TPA-M, SCCA, and CEA.

Study design

Serum levels of CYFRA 21-1, TPA-M, SCCA, and CEA were measured in 136 patients with a histologically proven SCCHN before and after treatment and in 125 healthy subjects, as controls. We evaluated the sensitivity and specificity of these tumor markers and to correlate, their levels with tumor staging, grading, or performance status.

Results

The study showed that none of the above markers presented satisfactory specificity and sensitivity in early diagnosis. In comparison with the other markers. TPA-M was the most effective of all markers and indicated a positive correlation with the grade of differentiation and nodal status. A remarkable correlation between high levels of TPA-M and CYFRA 21-1 in advanced stages (III, IV) of cancer has been shown.

Conclusions

All the tumor markers that were studied have significant limitations in the early diagnosis of cancer, but TPA-M and CYFRA 21-1 may have a role in monitoring the success of therapy and follow up of patients with SCCHN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
€32.70 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Singapore)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Forastiere A, Koch W, Trotti A, Sidransky D. Medical progress—head and neck cancer. N Engl J Med 2001; 345: 1890–1900.

    Article  PubMed  CAS  Google Scholar 

  2. Landis SH, Murray T, Bolden S, Wingo PO. Cancer statistics. CA Cancer J Clin 1998; 48: 6–29.

    PubMed  CAS  Google Scholar 

  3. Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994; 21: 281–288.

    PubMed  CAS  Google Scholar 

  4. Fujieda S. Prognostic factors for head and neck cancer. Gan To Kagaku Ryoho 2001; 28, (Review Japanese) (4): 440–447.

    PubMed  CAS  Google Scholar 

  5. Dietz A. Epidemiology of laryngeal cancer. Laryngorhinootologie 2004; 83 (11): 771–772.

    Article  PubMed  CAS  Google Scholar 

  6. Schroder M, Meyer T. CEA studies in squamous cell carcinoma of the head and neck. HNO 1986; 34: 334–342.

    PubMed  CAS  Google Scholar 

  7. Straka M, Wagner R, Johnson J, Kachman K, Eibling D, The lack of utility of a tumour marker panel in head and neck carcinoma. Arch Otolaryng Head Neck Surg 1992; 118: 802–805.

    PubMed  CAS  Google Scholar 

  8. Rassekh C, Johnson J, Eibling E. Circulating markers in squamous cell carcinoma of the head and neck: a review. Oral Oncol Eur J Cancer 1994; 30B: 23–28.

    Article  CAS  Google Scholar 

  9. Copper MP, Braakhuis JM, De Vries N, Van Dongen GA, Nauta J, Snow GB. A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials. Cancer Lett 1993; 71(3): 825–830.

    CAS  Google Scholar 

  10. Carbayo M, et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 1999; 45: 1944–1953.

    Google Scholar 

  11. Deng YF, et al. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J of Laryngol & Otol 2003; 117: 190–194.

    Article  Google Scholar 

  12. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004; 37(7): 529–540.

    Article  PubMed  CAS  Google Scholar 

  13. Ho S, Leung WT, Yuen J, Johnson PJ. Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy. Oral Oncol Eur. J. Cancer 1996; 32B(6): 377–380.

    Article  CAS  Google Scholar 

  14. Molina R, et al. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC. Anticancer Res 1995; 15: 479–484.

    PubMed  CAS  Google Scholar 

  15. Tannapfel A, Weber A. Tumor markers in squamous cell carcinoma of the head and neck: clinical effectiveness and prognostic value. Eur Arch Otorhinolayngol 2001; 258: 83–88.

    Article  CAS  Google Scholar 

  16. Ogawa T et al. Comparison of tumor markers in patients with suamous cell carcinoma of the head and neck. Acta Otolaryngol (Stockh) 1999; 540 (Suppl): 72–76.

    CAS  Google Scholar 

  17. Rosati G, Riccardi F, Tucci A. Use of tumor markers in the management of head and neck cancer. Int J Biol Markers 2000; 15(2): 179–183.

    PubMed  CAS  Google Scholar 

  18. Becciolini A, Porciani S, Lanini A, Tommasi M, Olmi P, Chiavacci A. Prognostic significance of tissue polypeptide antigen (TPA) in head and neck carcinomas. Acta Otolaryngol 1993; 32(3): 295–299.

    CAS  Google Scholar 

  19. Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M, Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryng Head Neck Surg 1995; 121: 177–181.

    PubMed  CAS  Google Scholar 

  20. Banal A, Hacene K, Berthelot-Ruff E, Mahe E, Fontana X, Pichon MF. Comparison of Cyfra 21-1 and SCCassays in head and neck tumours. Tumour Biol. 2001; 22(1): 27–35.

    Article  PubMed  CAS  Google Scholar 

  21. Niemann AM, Goeroegh T, Gottschlich S, Lippert BM, Werner JA. Cut off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Anticancer Res 1997; 17: 2859–2860.

    PubMed  CAS  Google Scholar 

  22. Ma B, et al. Prospective validation of serum CYFRA 21-1, β2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy. Cancer Lett 2004; 101(4): 776–781.

    CAS  Google Scholar 

  23. Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatof M, Laufer D. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer/Radiotherapy 1999; 85(5): 1018–1025.

    CAS  Google Scholar 

  24. Tai CJ, Liu FY, Liang JA, Yang SN, Tsai MH, Kao CH. Comparison of Cyfra 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma. Anticancer Res 2002; 22: 3793–3796.

    PubMed  Google Scholar 

  25. Nap M, Van Wek T, Andres C, Bellanger L. Immunohistochemical profiles of 30 monoclonal antibodies against cytokeratin 8, 18 and 19. Tumor Biol 2001; 22: 4–10.

    Article  CAS  Google Scholar 

  26. Hamakawa H, Bao Y, Takarada M, Fukuzumi M, Tanioka H. Cytokeratin expression in squamous cell carcinoma of the lung and oral cavity. An immunohistochemical study with possible clinical relevance. Oral Surgery Oral Medicine Oral Pathology 1998; 85(4): 438–443.

    CAS  Google Scholar 

  27. Kulpa J, Stasik Z, Skolyszewski J, Wojcik E, Rychlik U, Pudelek K. Predictive value of SCC-Ag, CYFRA 21-1 and selected acute phase proteins in radiotherapy of pharyngeal and laryngeal cancer. A preliminary report. Neoplasma 2004; 51(2): 103–109.

    PubMed  CAS  Google Scholar 

  28. Bongers V, Braakhuis JM, Snow GB. Circulating fragments of cytokeratin 19 in patients with head and neck squamous cell carcinoma. Clin Otolaryngol 1995; 20: 479–482.

    PubMed  CAS  Google Scholar 

  29. Kuropkat C, Lippert BM, Werner JA. Follow-up with serum cyfra 21-1 in patients with squamous sell carcinoma of the head and neck. Oncology 2002; 63: 280–285.

    Article  PubMed  CAS  Google Scholar 

  30. Lin WY, Yen TC, Cheng KY, Wang SJ. The value of Cyfra 21-1, a new tumor marker, in nasopharyngeal carcinoma. Neoplasma 1998;, 45(1): 21–24.

    PubMed  CAS  Google Scholar 

  31. Lee JK, Hsieh JF, Tsai SC, Ho YJ, Sun SS, Kao CH. Comparison of Cyfra 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 2001; 110(8): 775–778.

    PubMed  CAS  Google Scholar 

  32. Yen TC, Lin WY, Kao CH, Cheng KY, Wang SJ. A study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol 1998; 23: 82–86.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology, University of Athens, “Hippokration” Hospital, Athens

    D. Kandiloros, A. Eleftheriadou MD, T. Chalastras, I. Yiotakis & E. Ferekidis

  2. Department of Biochemistry, Evangelismos Hospital, Athens

    L. Kyriou

Authors
  1. D. Kandiloros
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Eleftheriadou MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Chalastras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Kyriou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Yiotakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Ferekidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Eleftheriadou MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kandiloros, D., Eleftheriadou, A., Chalastras, T. et al. Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck. Med Oncol 23, 463–470 (2006). https://doi.org/10.1385/MO:23:4:463

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:23:4:463

Key Words

Search

Navigation